# Expanded Access for ATB200/AT2221 for the Treatment of IOPD

> **NCT04327973** · — · AVAILABLE · sponsor: **Amicus Therapeutics**

## Conditions studied

- Pompe Disease Infantile-Onset

## Interventions

- **BIOLOGICAL:** ATB200
- **DRUG:** AT2221

## Key facts

- **NCT ID:** NCT04327973
- **Lead sponsor:** Amicus Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04327973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04327973, "Expanded Access for ATB200/AT2221 for the Treatment of IOPD". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT04327973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*